AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00406874
Drug: omega 3 fats
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg daily
Trial: NCT00406874
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 micrograms daily
Trial: NCT05027126
Drug: Fixed dose Dexketoprofen-Vitamin B Complex
RxNorm normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
Trial: NCT01522521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (i.v.)/year + daily calcium and vitamin D for 2 years
Trial: NCT01424891
Drug: Simvastatin 80 mg
RxNorm normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment with 80 mg of simvastatin over a period of 8 weeks
Trial: NCT01424891
Drug: Sim10/Eze10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
Trial: NCT01424891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with placebo over 8 weeks
Trial: NCT00347438
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
Trial: NCT00949754
Drug: honeybee venom (Apitoxin (Korea) Apitox (USA))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple intradermal injections of 100 ug pure honeybee venom
Trial: NCT03334851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
Trial: NCT01598883
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 U/kg
Trial: NCT02873065
Drug: Esoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01082874
Drug: Placebo ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
Trial: NCT01194089
Drug: Nasal Normal Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An isotonic solution of sodium chloride 0.65% in deionized water
Trial: NCT02514694
Drug: LEO32731
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00764387
Drug: Gadovist® (Gadobutrol, BAY86-4875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,1 mmol/kg of body weight in the vein, single administration
Trial: NCT00569244
Drug: Drug: YAZ flex (SH T00186D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
Trial: NCT00875238
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03691844
Drug: AMZ001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac gel
Trial: NCT03691844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03691844
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac gel
Trial: NCT02563860
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose escallating
Trial: NCT00496392
Drug: Nasal fentanyl
RxNorm normalized name: fentanyl Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakthrough pain in patients with breast or prostate cancer
Trial: NCT03371563
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with antibiotics for Lyme disease.
Trial: NCT04392141
Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
Trial: NCT03910738
Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
Trial: NCT03910738
Drug: Placebo 4 mL Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
Trial: NCT01425450
Drug: HF1020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
Trial: NCT01425450
Drug: HF1020 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose: HF1020 placebo capsule
Trial: NCT04452435
Drug: C21
RxNorm normalized name: C18-C21 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21
Trial: NCT04452435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03399955
Drug: Paromomycin
RxNorm normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin (20 mg/kg/d) IM for 14 days
Trial: NCT00746174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet PO daily for 16 weeks
Trial: NCT03677466
Drug: Pharmaco-invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography.
Trial: NCT03793439
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper corticosteroids starting at week 4
Trial: NCT03244059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An identically appearing placebo infusion.
Trial: NCT01344967
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
Trial: NCT00595231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg tablets
Trial: NCT01341457
Drug: LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT02502669
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00273520
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00600171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mulit-dose dry powder inhaler
Trial: NCT02421887
Drug: Antioxidant Supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
Trial: NCT02104414
Drug: Bupivacaine HCl with Epinephrine
RxNorm normalized name: Bupivacaine Hydrochloride/Epinephrine 0.25%-1:200000 Injection Solution [BUPIVACAINE HCL WITH EPINEPHRINE NOVAPLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg/30mL 0.25% Bupivacaine HCl with epinephrine
Trial: NCT02104414
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mL Normal Saline
Trial: NCT00103012
Drug: Gingko Biloba
RxNorm normalized name: Gingko Biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo Biloba 120 mg twice daily for 14 days
Trial: NCT02048345
Drug: Suspension Fed State
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02048345
Drug: Solution Fed State
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01418131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02959827
Drug: Iodinated contrast agents
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of iodine contrast agents and doses following the decision of the treating physician.
Trial: NCT01920568
Drug: Zoledronic acid 4 mg
RxNorm normalized name: zoledronic acid 4 MG
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
Trial: NCT01920568
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
Trial: NCT01920568
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
Trial: NCT00003603
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003603
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04072601
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
Trial: NCT03256903
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
Trial: NCT00883870
Drug: Plasmalyte A
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT04290793
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m\^2 d1 iv Q2W for 4 cycles
Trial: NCT04290793
Drug: Taxanes
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
Trial: NCT00405964
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, once daily for 12 weeks
Trial: NCT01357135
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01357135
Drug: Antihyperglycemic Medication
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01144975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
Trial: NCT00008190
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01505894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT00788320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times a week for 8 weeks
Trial: NCT01846663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral, 0 mg BID, 6 months of treatment
Trial: NCT01371812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
Trial: NCT05174195
Drug: Implanon NXT® subdermal implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inserted immediately
Trial: NCT05596617
Drug: Oral bedtime melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different doses of oral bedtime melatonin
Trial: NCT00888329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02051153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02931929
Drug: 68Ga-NeoBOMB1, 2-vial kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
Trial: NCT03085628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40IU
Trial: NCT04286841
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
Trial: NCT02313870
Drug: clobetasol propionate + Methotrexate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
Trial: NCT02210689
Drug: clindamycin phosphate vaginal cream 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01377987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg, once daily before bed, for 7 days
Trial: NCT01736904
Drug: wXELIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
Trial: NCT01736904
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
Trial: NCT00744978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
Trial: NCT01000922
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual dose of RHI administered subcutaneously
Trial: NCT01000922
Drug: VIAject
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual dose of VIAject administered subcutaneously
Trial: NCT01000922
Drug: VIAject 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual dose of VIAject 50% administered subcutaneously
Trial: NCT04000308
Drug: Wound Infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
Trial: NCT03587025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00511043
Drug: PTK787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
Trial: NCT00603239
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
Trial: NCT02095665
Drug: Tylenol #3
RxNorm normalized name: Tylenol #3 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
Trial: NCT00223977
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg ferrous sulfate orally three times daily x 8 weeks
Trial: NCT03822455
Drug: OligoG DPI
RxNorm normalized name: capryl oligoglucoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OligoG Dry Powder for Inhalation
Trial: NCT02359045
Drug: D1400147
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A
Trial: NCT02359045
Drug: D14000136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B
Trial: NCT02359045
Drug: D14000137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C
Trial: NCT02359045
Drug: Epanova®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment D
Trial: NCT03479294
Drug: Shenlingcao Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
Trial: NCT02708849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose placebo
Trial: NCT00904098
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment used to treat all migraine headaches
Trial: NCT01588314
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compounded placebo capsules
Trial: NCT01190254
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: asenapine-matched placebo tablets for sublingual administration
Trial: NCT02493257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01303146
Drug: rhARSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion 100U/kg every other week for 18 months
Trial: NCT01456208
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A hormone that is normally present in your body, which regulates your blood pressure.
Trial: NCT02655523
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of preservative free normal saline
Trial: NCT03515551
Drug: IMCnyeso
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IV infusions of IMCnyeso
Trial: NCT04170504
Drug: Qing Re Huo Xue (QRHX) granule
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
Trial: NCT04170504
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate 10 mg per week for 24 weeks.
Trial: NCT04170504
Drug: Qing Re Huo Xue (QRHX) granule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
Trial: NCT01391572
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00907530
Drug: MULTIHANCE:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MULTIHANCE ® 0.5 M,0.1 mmol/kg
Trial: NCT00530829
Drug: zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
Trial: NCT00143702
Drug: Riboflavin and Thiamine (Supplementation)
RxNorm normalized name: niacin / riboflavin / thiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description.
Trial: NCT01115894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01986309
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% infusion
Trial: NCT00763685
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120 mg, paracetamol 1 g
Trial: NCT03597529
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: melatonin
Trial: NCT03972345
Drug: Norditropin® FlexPro®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
Trial: NCT03648489
Drug: TAK228
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please refer to arm/group description
Trial: NCT02298179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.